Vanguard Group Inc. Has $20.91 Million Stock Holdings in Pulmonx Co. (NASDAQ:LUNG)

Vanguard Group Inc. lifted its stake in shares of Pulmonx Co. (NASDAQ:LUNG) by 1.0% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 2,023,836 shares of the company’s stock after buying an additional 19,364 shares during the quarter. Vanguard Group Inc. owned about 5.28% of Pulmonx worth $20,906,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. American Century Companies Inc. lifted its stake in shares of Pulmonx by 43.9% during the 3rd quarter. American Century Companies Inc. now owns 22,431 shares of the company’s stock worth $232,000 after buying an additional 6,843 shares during the last quarter. Walleye Trading LLC acquired a new stake in shares of Pulmonx during the 3rd quarter worth about $164,000. Walleye Capital LLC acquired a new stake in shares of Pulmonx during the 3rd quarter worth about $3,846,000. Morgan Stanley lifted its stake in shares of Pulmonx by 12.5% during the 3rd quarter. Morgan Stanley now owns 2,219,826 shares of the company’s stock worth $22,931,000 after buying an additional 246,302 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Pulmonx by 1,092.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,756 shares of the company’s stock worth $121,000 after buying an additional 10,770 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Price Performance

LUNG stock opened at $7.89 on Friday. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. Pulmonx Co. has a 12 month low of $7.72 and a 12 month high of $14.84. The firm has a market cap of $304.08 million, a P/E ratio of -4.93 and a beta of 0.60. The company’s 50-day moving average price is $10.46 and its two-hundred day moving average price is $10.89.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, February 21st. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. Pulmonx had a negative net margin of 88.60% and a negative return on equity of 46.63%. The firm had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.24 million. During the same period last year, the firm earned ($0.38) EPS. The business’s quarterly revenue was up 25.3% compared to the same quarter last year. On average, analysts anticipate that Pulmonx Co. will post -1.79 earnings per share for the current fiscal year.

Insider Activity at Pulmonx

In related news, General Counsel David Aaron Lehman sold 4,351 shares of Pulmonx stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $39,420.06. Following the sale, the general counsel now directly owns 145,488 shares of the company’s stock, valued at approximately $1,318,121.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, General Counsel David Aaron Lehman sold 4,351 shares of Pulmonx stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $39,420.06. Following the sale, the general counsel now directly owns 145,488 shares of the company’s stock, valued at approximately $1,318,121.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Geoffrey Beran Rose sold 3,097 shares of Pulmonx stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $28,058.82. Following the sale, the insider now directly owns 239,952 shares in the company, valued at $2,173,965.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 49,032 shares of company stock valued at $603,390. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LUNG. Stifel Nicolaus raised their price target on shares of Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 price target (down from $16.00) on shares of Pulmonx in a research report on Friday, February 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research report on Wednesday, April 3rd. Finally, Citigroup raised their price target on shares of Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Pulmonx currently has an average rating of “Moderate Buy” and an average price target of $15.83.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.